Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

0.4694
+0.03658.43%
Volume:22.16M
Turnover:10.49M
Market Cap:11.96M
PE:-0.43
High:0.5129
Open:0.3951
Low:0.3948
Close:0.4329
52wk High:2.05
52wk Low:0.1593
Shares:25.48M
Float Shares:24.18M
Volume Ratio:0.39
T/O Rate:91.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0878
EPS(LYR):-1.5837
ROE:-241.14%
ROA:-118.81%
PB:3.95
PE(LYR):-0.30

Loading ...

BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake

TIPRANKS
·
May 27

Kaos Capital discloses 4.9% stake in BioRestorative Therapies

Reuters
·
May 27

Kaos Capital: Urgently Seeks Meeting With BioRestorative Therapies Board to Discuss Unlocking Shareholder Value

THOMSON REUTERS
·
May 27

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (Nasdaq: Brtx)

THOMSON REUTERS
·
May 27

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

TIPRANKS
·
May 27

BioRestorative completes Phase 2 dosing of BRTX-100 in chronic lumbar disc disease trial, targets Q2 2027 data

Reuters
·
May 26

BioRestorative Therapies Inc - Topline Phase 2 Data for Brtx-100 Expected in Q2 2027

THOMSON REUTERS
·
May 26

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

GlobeNewswire
·
May 26

BioRestorative Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BioRestorative Q1 FY26 net loss narrows to $2.15 million; revenue falls 7.32% to $23,170

Reuters
·
May 15

BioRestorative Therapies presents preclinical data on MSC exosome proteomics

TIPRANKS
·
May 14

BioRestorative presents preclinical exosome data at ISCT 2026 annual meeting

Reuters
·
May 13

BioRestorative Therapies Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
May 08

BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100

TIPRANKS
·
May 08

BioRestorative reports Phase 2 BRTX-100 data showing 52% hit pain, function endpoint

Reuters
·
May 08

BioRestorative Therapies Inc - 52-Week Cohort Increases to 25 Patients With No Dose-Limiting Toxicity Safety Signals

THOMSON REUTERS
·
May 08

BioRestorative Therapies Inc - 52% of Patients Achieve ≥50% Improvement in Vas Pain and Odi Function at 52 Weeks

THOMSON REUTERS
·
May 08

BioRestorative awards 2025 cash bonuses to CEO, other top executives

Reuters
·
May 02

BioRestorative to present new Phase 2 lumbar disc disease trial data at ISCT 2026

Reuters
·
Apr 30

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for lumbar disc disease

Reuters
·
Apr 24